InvestorsHub Logo

Esa

Followers 11
Posts 415
Boards Moderated 0
Alias Born 02/21/2011

Esa

Re: None

Tuesday, 08/03/2021 2:45:28 PM

Tuesday, August 03, 2021 2:45:28 PM

Post# of 2139
Lead Drug Candidate
CRV431, a cyclophilin inhibitor

NASH
• Severe form of fatty liver disease affects about 17 million people in the US
• No approved drugs for treatment of NASH
• May result in liver cirrhosis, liver transplant, liver cancer, death
• Huge market potential projected to reach $54 Billion USD by 2027

CASH ON HAND
$115.4 M
as of 3/31/21

SHARES 76.2M

APPROX. BURN RATE
PER QUARTER $5-6 M
will increase as
Phase 2b NASH trial
progress is made

Enough cash on hand to cover all costs of programs
through end of Phase 2b (about 3 years in cash),
assuming no expansion into other areas/projects

https://hepionpharma.com/wp-content/uploads/2021/07/2021-Hepion-Fact-Sheet-FINAL.pdf

Market Cap 110 M
$HEPA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News